Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 475 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ALS Clear all
Recruiting No phase listed Observational

Amyotrophic Lateral Sclerosis (ALS) Families Project

NCT03865420
View directory record Official record
Conditions
ALS
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 105 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

Collection of Blood Samples for DNA in Motor Neuron Disease

NCT00362362
View directory record Official record
Conditions
Motor Neuron Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Adenosine 2A Receptor Antagonism and AIH in ALS

NCT05377424
View directory record Official record
Conditions
ALS
Interventions
Consume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug, SHAM counterpart to low oxygen therapy.
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04569435
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ANX005
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot)

NCT03214224
View directory record Official record
Conditions
ALS
Interventions
remote pulmonary function testing, standard pulmonary function testing
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Safety of Caprylic Triglycerides in ALS: A Pilot Study

NCT02716662
View directory record Official record
Conditions
ALS
Interventions
Axona
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

NCT05978908
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
FC-12738, Saline
Drug
Lead sponsor
Neurodegenerative Disease Research Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04165824
View directory record Official record
Conditions
ALS
Interventions
MT-1186
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Phoenix, Arizona • Rogers, Arkansas • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

NCT05053035
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AL001, Placebo
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Not applicable Interventional

A Mindful Community for People With ALS and Their Primary Caregivers

NCT05595850
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Caregiver Burden
Interventions
Mindfulness, Mindful Learning
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Not listed No phase listed Observational

A Study to Evaluate the Performance of a Diagnostic Test in ALS

NCT02759913
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Lumbar puncture
Procedure
Lead sponsor
Iron Horse Diagnostics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
50 mg Usnoflast, 75 mg Usnoflast, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers

NCT01495390
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Nervous System Diseases, Sclerosis, Motor Neuron Disease, Spinal Cord Diseases, Central Nervous System Diseases, Neurodegenerative Diseases, Neuromuscular Diseases, ALS
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MN-166, placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
10
States / cities
Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

NCT04993755
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions
TPN-101, 400 mg/day, Placebo
Drug
Lead sponsor
Transposon Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
La Jolla, California • Orange, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Not listed Phase 1Phase 2 Interventional

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

NCT04987671
View directory record Official record
Conditions
ALS
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

Screening and Natural History: Primary Lateral Sclerosis and Related Disorders

NCT00015444
View directory record Official record
Conditions
Primary Lateral Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT03225144
View directory record Official record
Conditions
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

NCT00070993
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine monohydrate
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Jul 22, 2026, 4:05 PM EDT
Not listed No phase listed Observational

Accurate Test of Limb Isometric Strength (ATLIS) in ALS

NCT02374606
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Answer ALS: Individualized Initiative for ALS Discovery

NCT02574390
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Flail Arm ALS, Progressive Muscular Atrophy, Monomelic Amyotrophy, Motor Neuron Disease, Asymptomatic ALS Gene Carriers, Healthy Controls
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,049 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Tocilizumab in ALS Subjects

NCT02469896
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
Interventions
Tocilizumab, Placebo
Drug · Other
Lead sponsor
Barrow Neurological Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Kansas City, Kansas • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)

NCT03506425
View directory record Official record
Conditions
ALS
Interventions
Triheptanoin
Drug
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jul 22, 2026, 4:05 PM EDT